CureVac N.V. (CVAC)
NASDAQ: CVAC · Real-Time Price · USD
3.190
0.00 (0.00%)
Apr 23, 2025, 4:00 PM EDT - Market closed
CureVac Revenue
In the year 2024, CureVac had annual revenue of 535.18M EUR with 895.54% growth. CureVac had revenue of 254.19M in the quarter ending December 31, 2024, with 1,026.36% growth.
Revenue (ttm)
535.18M EUR
Revenue Growth
+895.54%
P/S Ratio
1.28
Revenue / Employee
544,435 EUR
Employees
983
Market Cap
718.25M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
CVAC News
- 13 days ago - CureVac N.V. (CVAC) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 13 days ago - CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update - Accesswire
- 15 days ago - CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025 - Accesswire
- 16 days ago - CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer - Accesswire
- 26 days ago - CureVac Shares Rise on Patent Confirmation Amid BioNTech Lawsuit - Market Watch
- 26 days ago - European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps - Benzinga
- 27 days ago - European Patent Office declares CureVac mRNA patent valid - Reuters
- 27 days ago - CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE - Accesswire